Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$173.00 USD

173.00
994,173

-0.27 (-0.16%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $172.98 -0.02 (-0.01%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks News

Zacks Equity Research

GEHC Stock Rises as FDA Clears MIM Software's Centiloid Tool

GE Healthcare's MIM Software announces the receipt of FDA clearance for its Centiloid scaling tool to perform PET-based amyloid imaging.

Zacks Equity Research

CAH Stock May Gain Following the Distribution Agreement With Telix

Cardinal Health and Telix announce an agreement selecting the former as a commercial radiopharmaceutical distributor to supply finished unit doses of Telix's Zircaix.

Zacks Equity Research

Here's Why You Should Retain Accuray Stock in Your Portfolio Now

ARAY's solid product demand and revenue growth raise optimism about the stock.

Zacks Equity Research

NSPR Stock Declines Despite PMA Application Submission for CGuard

InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.

Zacks Equity Research

Tactile Medical's Shares Rise After PDAC Approval for Nimbl

TCMD's Nimbl pneumatic compression system gets CMS PDAC approval and is set to be launched in the United States soon, following FDA clearance for treating lymphedema.

Zacks Equity Research

DGX Stock Likely to Gain From Allina Health's Select Lab Assets Buyout

With the completion of the acquisition, Allina Health's clinic physicians will now have access to Quest Diagnostics' laboratory services.

Zacks Equity Research

CVRX Stock Gains on Unveiling of Barostim's Positive Study Data

CVRx announces the publication of positive study data for its Barostim therapy.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Masimo Stock Likely to Rise With Qualcomm Wear OS Partnership

MASI Collaborates with Qualcomm to develop a reference platform for Wear OS smartwatches, combining biosensing tech and Snapdragon chips to enhance performance and connectivity.

Zacks Equity Research

Merit Medical Gains 26.4% Year to Date: What's Driving the Stock?

MMSI's shares gain on the back of strength in its Cardiovascular segment and a robust product portfolio.

Zacks Equity Research

SNN Stock Declines Despite the Launch of Its Patient-Matched Guides

Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.

Zacks Equity Research

iRhythm's Zio ECG System Gets Approval in Japan, Stock Falls

IRTC's Zio ECG monitoring system gets approval in Japan, marking a significant step in revolutionizing arrhythmia diagnostics with AI-powered technology.

Zacks Equity Research

Avanos Medical Stock May Gain From Brand Partnership With NFL

AVNS' GAME READY announces a paid partnership with NFL defensive end and San Francisco 49ers star, Nick Bosa.

Zacks Equity Research

SYK Stocks Gains Following Expansion of Foot & Ankle Portfolio

Stryker unveils two new products, enhancing precision and outcomes in foot and ankle surgeries.

Zacks Equity Research

Factors Driving Veeva Stock More Than 20% in Three Months

Robust quarterly results on the back of new partnerships and rising subscription revenues are driving VEEV's shares.

Zacks Equity Research

Why Brookdale May Not Be a Safe Bet Despite 34-Month Occupancy Growth

Rising operating costs due to inflationary challenges in the senior living industry and higher estimated insurance expenses are likely to keep BKD's margins under pressure.

Zacks Equity Research

PacBio Stock Drops After Singapore Collaboration for HiFi Sequencing

PACB's HiFi sequencing powers the HiFi Consortium's global effort to enhance the diagnosis and treatment of subfertility and recurrent pregnancy loss.

Zacks Equity Research

Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes

LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.

Zacks Equity Research

Solventum Shares May Gain on the Launch of Its New V.A.C Therapy

SOLV announces the launch of its V.A.C. Peel and Place Dressing for providing efficient and effective care in case of negative pressure wound therapy.

Zacks Equity Research

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

Zacks Equity Research

PacBio's Stock Up on Munster Deal for Male Infertility Research

PACB collaborates with the University Hospital of Munster, using Revio HiFi sequencing to advance research on male infertility and rare diseases in Germany and globally.

Zacks Equity Research

Paragon 28 Stock Gains From the Latest Launch of Its Right-Angle Drill

FNA launched the Right-Angle Drill to enhance the APEX 3D Total Ankle Replacement System. The drill is designed to improve tibia preparation.

Zacks Equity Research

Glaukos Stocks Rides on Strong Product Demand Amid Competition

GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.

Zacks Equity Research

MASI Stock Down Despite New SafetyNet Deal for Neonatal Care

The latest adoption of Masimo's SafetyNet is likely to improve the care provided to premature newborns and facilitate their early discharge from the hospital.

Zacks Equity Research

iRhythm Stock Gains Following Favorable Zio Monitor Study Data

IRTC announces initial findings demonstrating the superior real-world performance of the next-generation Zio LTCM Monitor at the HRX 2024 meeting.